Loading
A phase 2 trial of AK146D1, Ivonescimab, Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, now recruiting.
A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07669779 by Akeso, with 348 participants planned, started 2026-07-10 and due to reach its primary completion in 2027-08-30. Interventions recorded: AK146D1 for injection, AK112 Injection, Platinum chemotherapy, Osimertinib. Conditions listed: Advanced Non Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares AK146D1, Bispecific ADC, Akeso.
Shares Akeso, Ivonescimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Akeso, Ivonescimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Akeso, Ivonescimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Akeso, Ivonescimab, Small-cell lung cancer.
Shares Akeso, Ivonescimab, Non-small-cell lung cancer.
Shares Akeso, Ivonescimab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Akeso, Ivonescimab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/